Ikarovec Limited is a biotechnology/gene therapy company focused on developing novel and differentiated treatments for major ophthalmic (eye) diseases. The Company is developing a one-time gene therapy designed to preserve vision in patients with Age-related Macular Degeneration (AMD) and Geographic Atrophy.

Ikarovec's proprietary technology platform builds on validated therapeutic approaches and adds synergistic second mechanisms, addressing what current single-pathway therapies miss with reduced development risk.

The Company's lead programs address large market opportunities including geographic atrophy (a leading cause of blindness), wet age-related macular degeneration, diabetic macular edema, and ocular hypertension.

The Company's approach uses next-generation, dual-pathway gene therapies.